New registered manufacturer is publicly announced

in page functions

With the June launch of the pilot AMC against pneumococcal disease, manufacturers are now registering to participate

Geneva, 30 September 2009 - Panacea Biotect Ltd and the Serum institute of India are two of the companies that have begun the registration process in order to participate. Several companies have inquired about the pilot.

Information about the number and names of manufacturers is confidential unless a firm requests its information to be made public.

For more information about the AMC registration process please contact: amc@gavialliance.org

US$ 80-100 billion

Investing in Gavi’s 2016-2020 strategy has the potential to deliver US$ 80-100 billion in costs averted related to illness, such as productivity loss due to death/disability, treatment costs, caretaker productivity loss and transport costs.

Stack M et al. Estimated economic benefits during Decade of Vaccines, Health Affairs 2011

More facts...

close icon

modal window here